Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2017 ASCO Annual Meeting /
Alectinib eclipses crizotinib for ALK positive lung cancer

2nd - 6th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 1912

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Dr Shaw speaks with ecancer at ASCO 2017 about results from the ALEX trial of alectinib, a next-generation ALK inhibitor, for patients with lung cancer containing ALK mutations.

She describes the significant benefits of alectinib over crizotinib, with progression free survival at 25.7 months compared to 10.4 months, fewer side effects and a reduced incidence of brain metastases.

Overall, Dr Shaw encourages the use of alectinib as the new standard of care, and for doctors to discuss its use with patients currently receiving crizotinib.

Watch Dr Shaw present these results at a press briefing session here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation